Tweet
09:49 | Lima, Jun. 27.
ANDINA
To date, the National Health Institute (INS) has performed genomic sequencing on 2,010 samples from patients diagnosed with COVID-19, which were collected through RT-PCR testing from January to June this year and analyzed in the genomic surveillance platform set up at the biomedicine laboratory, the Ministry of Health (Minsa) reported on Sunday.
The tests come from 24 regions across Peru, including the Constitutional Province of Callao, where the predominance of the Lambda variant (C37) has been observed in 1,416 (70.9%) of the tested cases.
ANDINA
To date, the National Health Institute (INS) has performed genomic sequencing on 2,010 samples from patients diagnosed with COVID-19, which were collected through RT-PCR testing from January to June this year and analyzed in the genomic surveillance platform set up at the biomedicine laboratory, the Ministry of Health (Minsa) reported on Sunday.
The tests come from 24 regions across Peru, including the Constitutional Province of Callao, where the predominance of the Lambda variant (C37) has been observed in 1,416 (70.9%) of the tested cases.